Explore

Rapid Read Rapid Read
Beverly Davidson Presents Advances in Huntington’s Disease Gene Therapy at ASGCT 2026

Beverly Davidson Presents Advances in Huntington’s Disease Gene Therapy at ASGCT 2026

Geneticist Beverly Davidson, PhD, received the 2026 Outstanding Achievement Award from the American Society of Gene and Cell Therapy (ASGCT) for her work in developing gene therapies for central nervous system disorders, including Huntington’s disease (HD). Davidson's research focuses on improving adeno-associated viruses (AAVs) for CNS gene therapies, with a lead program targeting HD. Her work addresses challenges in gene therapy delivery to the brain, aiming to enhance scalability and potency for treating genetic diseases.
Rapid Read Rapid Read
Beverly Davidson Advances Gene Therapy for Huntington's Disease with Novel AAVs

Beverly Davidson Advances Gene Therapy for Huntington's Disease with Novel AAVs

Beverly Davidson, PhD, a geneticist and chief scientific strategy officer at the Children's Hospital of Philadelphia, has been recognized with the 2026 Outstanding Achievement Award by the American Society of Gene and Cell Therapy (ASGCT). Davidson's work focuses on developing novel adeno-associated viruses (AAVs) to target central nervous system disorders, particularly Huntington's disease (HD). Her research, conducted at Latus Bio, a biotech company she co-founded, aims to improve the delivery and potency of gene therapies for HD. Davidson's team has engineered AAVs to better target neuronal cells, overcoming challenges such as scalability and high peripheral exposure. The research includes the development of AAV-DB-3, a capsid that shows promise in targeting deep brain regions crucial for HD treatment.
Rapid Read Rapid Read
Genetic Survey Reveals Flaws in Mouse Models, Impacting Biomedical Research

Genetic Survey Reveals Flaws in Mouse Models, Impacting Biomedical Research

A recent study published in Science has uncovered significant inconsistencies in the genetic makeup of laboratory mice, which are widely used in biomedical research. The research, led by Fernando Pardo-Manuel de Villena from the University of North Carolina at Chapel Hill, analyzed the genomes of hundreds of mouse strains. The findings revealed that nearly half of the strains did not match their reported genetic profiles. This discrepancy poses a risk to the reproducibility of research findings, as the genetic differences between strains can lead to misinterpretations of how diseases function. The study highlights the challenges in maintaining genetic purity when transferring genetic modifications, such as gene knockouts, across different mouse strains. The research was conducted using samples from the Mutant Mouse Research and Resource Centers, a network established by the US National Institutes of Health to preserve and share mouse strains.
Rapid Read Rapid Read
DNA-Guided CRISPR System Offers New Possibilities for RNA Editing

DNA-Guided CRISPR System Offers New Possibilities for RNA Editing

Researchers at the University of Florida have developed a novel CRISPR system that uses DNA guides instead of RNA to target RNA molecules. This new platform, called ΨDNA, reprograms Cas12 nucleases to recognize RNA targets, offering a more stable and precise method for RNA editing. The study, published in Nature Biotechnology, demonstrates that ΨDNA can achieve high accuracy in detecting hepatitis C virus RNA and effectively knock down endogenous RNA transcripts in human cell lines. This approach could extend the applications of CRISPR beyond genome editing to include precise control of cellular transcriptomes.
Trendline Trendline
A*STAR Unveils Technique to Analyze RNA Structures for Disease Research

A*STAR Unveils Technique to Analyze RNA Structures for Disease Research

A*STAR Unveils Technique to Analyze RNA Structures for Disease Research
Rapid Read Rapid Read
Scientists Identify CIRBP Protein as Key to Longevity and Cancer Resistance

Scientists Identify CIRBP Protein as Key to Longevity and Cancer Resistance

Researchers at the University of Rochester have identified a protein, CIRBP, that plays a crucial role in repairing DNA damage, potentially extending lifespan and reducing cancer risk. The study, published in Nature, highlights how CIRBP helps repair double-strand DNA breaks, a type of genetic damage linked to aging and disease. The research was inspired by the bowhead whale, a species known for its long lifespan and low cancer rates. The team is exploring ways to increase CIRBP levels in humans, possibly through lifestyle changes like cold exposure, as the protein responds to lower temperatures. However, these ideas are in early stages, and further testing is needed to determine their efficacy in humans.
Rapid Read Rapid Read
Researchers Identify SHP Protein as Potential Osteoarthritis Treatment

Researchers Identify SHP Protein as Potential Osteoarthritis Treatment

In a groundbreaking study published in Nature Communications, researchers have identified a protein called SHP (NR0B2) that could play a crucial role in treating osteoarthritis. The study, led by Dr. Chul-Ho Lee and Dr. Yong-Hoon Kim from the Korea Research Institute of Bioscience and Biotechnology, in collaboration with Prof. JinHyun Kim at Chungnam National University Hospital, found that SHP acts as a natural defender of cartilage. The research revealed that SHP levels decline as osteoarthritis progresses, leading to accelerated joint deterioration. By restoring SHP in animal models, the researchers were able to reduce cartilage damage, improve joint function, and ease pain, suggesting that SHP could be a promising target for therapies aimed at slowing or halting the disease.
Rapid Read Rapid Read
CRISPR Technology Advances with New Method to Target and Destroy Cancer Cells

CRISPR Technology Advances with New Method to Target and Destroy Cancer Cells

Researchers have developed a new CRISPR system, Cas12a2, which can selectively target and destroy cancer cells while leaving healthy cells unharmed. This system acts as a self-destruct mechanism for diseased cells, differing from the traditional Cas9 system known for its precise DNA editing capabilities. The study, published in Nature, highlights Cas12a2's ability to identify and eliminate cells with specific RNA sequences, such as those carrying the cancer-driving KRAS mutation. In experiments with mice, a single treatment using this method reduced tumor volume by approximately 50%. The research suggests a shift in cancer treatment strategies, focusing on the selective elimination of harmful cells rather than broad-spectrum therapies.
Trendline Trendline
Longeveron Reports Q1 Financial Results and Strategic Updates

Longeveron Reports Q1 Financial Results and Strategic Updates

Longeveron Reports Q1 Financial Results and Strategic Updates
Trendline Trendline
Precision BioSciences Unveils Promising Preclinical Data for Duchenne Muscular Dystrophy Treatment

Precision BioSciences Unveils Promising Preclinical Data for Duchenne Muscular Dystrophy Treatment

Precision BioSciences Unveils Promising Preclinical Data for Duchenne Muscular Dystrophy Treatment
Trendline Trendline
Dyno Therapeutics Expands Frontiers Network to Enhance Genetic Medicine Development

Dyno Therapeutics Expands Frontiers Network to Enhance Genetic Medicine Development

Dyno Therapeutics Expands Frontiers Network to Enhance Genetic Medicine Development
Trendline Trendline
Dyno Therapeutics Unveils New AAV Capsids and AI Platform for Rare Disease Therapies

Dyno Therapeutics Unveils New AAV Capsids and AI Platform for Rare Disease Therapies

Dyno Therapeutics Unveils New AAV Capsids and AI Platform for Rare Disease Therapies